UK regulatory landscape
Tirzepatide (Mounjaro) in the UK: dispensing landscape
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-04
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Tirzepatide (Mounjaro) in the UK
Tirzepatide, marketed in the UK as Mounjaro, is a prescription-only medicine regulated by the MHRA. This page is a regulatory and dispensing-landscape reference, not a recommendation: it sets out the MHRA marketing authorisation, the NICE TA1026 pathway, the NHS England phasing, and the legitimate UK dispensing routes through NHS, private clinic and community pharmacy. Your UK-licensed prescriber decides whether tirzepatide is appropriate, based on the SmPC, PIL and your individual clinical picture.
NHS pathway
NHS England access
NICE TA1026 sets the clinical eligibility cohorts. Cohort 1 has been in active rollout since June 2025 (BMI 40+ with four or more weight-related comorbidities). Cohort 2 commences 23 June 2026 (BMI 35 to 39.9, four or more comorbidities). Beyond June 2026, eligibility extends progressively in later phases over up to 12 years; later cohort criteria have not yet been finalised by NHS England. Access is via specialist weight management services in line with ICB commissioning.
Read the NHS access editorial →
Private route
CQC-registered clinics
Independent CQC-registered providers in the UK that include tirzepatide on their formulary include Numan, Voy, Manual, and Juniper. These are app-based programmes coupling a prescriber consultation with ongoing clinical review. Whether this pathway is appropriate is a decision for your prescriber.
UK regulated clinic directory →
Pharmacy route
GPhC-registered pharmacies
UK pharmacies registered with the General Pharmaceutical Council that dispense tirzepatide after an online prescriber consultation include Phlo, Pharmacy2U, SimplyMeds, and Boots Online Doctor. Dispensing is contingent on a valid UK prescription issued by a registered prescriber.
UK regulated pharmacy directory →
Regulatory points worth knowing
- · Tirzepatide is POM throughout the UK. Supply outside a valid prescription issued by a UK-registered prescriber is unlawful under the Human Medicines Regulations 2012.
- · The MHRA has stated public enforcement activity against grey-import and unlicensed-supply channels, including significant seizures of trafficked weight-management medicines in early 2026. Falsified medicines do not have the assurance of the UK regulated supply chain.
- · The MHRA-approved SmPC lists pregnancy and breastfeeding among the contraindications. Suitability in any individual is a matter for the prescriber, referencing the SmPC and the PIL.
Further editorial: NHS access pathway · aftercare reference.
Important: POM, your UK-licensed prescriber decides
Tirzepatide (Mounjaro) is a prescription-only medicine. PeptideClear is an editorial publication, not a pharmacy, not a clinic, and not a prescriber. We do not sell, dispense, or recommend tirzepatide for any individual. We publish this page as a UK regulatory and dispensing-landscape reference. Your UK-licensed prescriber, working from the MHRA-approved SmPC, the PIL, NICE TA1026, and your clinical picture, decides whether tirzepatide is appropriate for you.
Frequently asked questions
Can I buy Mounjaro without a prescription in the UK?
No. Tirzepatide (Mounjaro) is a prescription-only medicine throughout the UK. Supply outside a valid prescription issued by a UK-registered prescriber is unlawful under the Human Medicines Regulations 2012. Whether it is appropriate for you is a decision for your prescriber.
What are the legitimate UK routes to tirzepatide?
Three routes exist in 2026: the NHS pathway via specialist weight management services under NICE TA1026 and ICB commissioning, CQC-registered private clinics, and GPhC-registered pharmacies dispensing after a prescriber consultation. Each still requires a valid UK prescription.
Who is eligible for tirzepatide on the NHS?
Eligibility is set by the NICE TA1026 cohorts, not by this page. Cohort 1 (BMI 40 or above with four or more weight-related comorbidities) has been in rollout since June 2025; Cohort 2 (BMI 35 to 39.9 with four or more comorbidities) commences 23 June 2026. Your specialist weight management service assesses eligibility.
Does PeptideClear sell tirzepatide?
No. PeptideClear is an editorial publication, not a pharmacy, clinic, or prescriber. This page documents the UK regulatory and dispensing landscape and points to the NHS, clinic, and pharmacy routes. We do not sell, dispense, or recommend tirzepatide for any individual.